{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-021434","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2022-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.889744+00:00","generated_at":"2026-06-25T06:49:14.485698+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PMV Pharma's PC14586 shows 30% partial response in higher dose cohorts at ASCO","bullets":["Abstract reports 3/10 (30%) partial responses in patients treated in higher dose cohorts of Phase 1/2 PYNNACLE trial.","Data from 29 patients (21 evaluable) across multiple tumor types with p53 Y220C mutation; safety profile well-tolerated.","Dose-proportional increases in Cmax and AUC observed; updated data to be presented in oral session on June 7, 2022.","Company to host investor webcast on June 7 at 6:30 PM CDT to review data."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-021434","json":"https://secwatch.observer/filing/0001564590-22-021434.json","markdown":"https://secwatch.observer/filing/0001564590-22-021434.md","text":"https://secwatch.observer/filing/0001564590-22-021434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000156459022021434/0001564590-22-021434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000156459022021434/pmvp-8k_20220526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T06:49:14.485698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}